SCHEMBL3387494

SCHEMBL3387494

NC(c1ccccn1)c1nc(N2CCOCC2)nc2scc(-c3ccc(F)cc3)c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.44
MAPT P10636 3/20 0.44
KDM4E B2RXH2 3/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
LMNA P02545 2/20 0.42
STK4 Q13043 1/20 0.39
STK3 Q13188 1/20 0.39
LRRK2 Q5S007 1/20 0.39
NPC1 O15118 1/20 0.39
AR P10275 1/20 0.39
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 2/20 0.37
CYP1A2 P05177 1/20 0.37
HPGD P15428 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2368516 0.93 LMNA (0.50) HTTMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL3387613 0.81 KDM4E (0.48) MAPTKDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL3386731 0.80 LMNA (0.39) HTTMAPTKDM4EMEN1KMT2A
SCHEMBL3385329 0.80 LMNA (0.44) HTTMAPTKDM4ESMN1; SMN2NPSR1
SCHEMBL3383761 0.80 LMNA (0.55) HTTMAPTKDM4EMEN1KMT2A
SCHEMBL2368668 0.78 LMNA (0.55) HTTMAPTKDM4EMEN1KMT2A
SCHEMBL3387950 0.77 LMNA (0.52) HTTMAPTKDM4EMEN1KMT2A
SCHEMBL3387496 0.76 CSNK1D (0.51) HTTMAPTKDM4EMEN1KMT2A
SCHEMBL4864904 0.76 STK4 (0.38) HTTMAPTKDM4ENPSR1TDP1
SCHEMBL2903658 0.71 LMNA (0.43) HTTMAPTKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 HTT 543/4885MAPT 2978/4885KDM4E 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.